ZMB Member Ulf Dittmer
ZMB Member
Ulf Dittmer
Next ZMB-Member
Prof. Dr. Ulf Dittmer
Director of:
Institute of Virology
University Hospital Essen
Hufelandstr. 55
45147 Essen
- +49 201 723 3693
- Website
- Selected Publications
- Publication Metrics
- ZMB Research Program
Immunology, Infectious Diseases and Transplantation
Research Overview
- Persistent viral infections
- Innate immunity to retroviruses
- Basics of cellular and molecular immune defense mechanisms
- Immune regulation in retrovirus infections
- Immunotherapy for retroviral infections and virus-induced tumors
- Development of vaccines against retroviruses
- Antiviral activity of interferons
Selected Publications
-
HLA class II loss and JAK1/2 deficiency coevolve in melanoma leading to CD4 T cell and IFNγ cross-resistanceIn: Clinical Cancer Research Vol. 29 (2023) Nr. 15, pp. 2894 - 2907Online Full Text: dx.doi.org/
-
Impaired humoral immunity to BQ.1.1 in convalescent and vaccinated patientsIn: Nature Communications Vol. 14 (2023) Nr. 1, 2835Online Full Text: dx.doi.org/ (Open Access)
-
Single-cell analysis of memory B cells from top neutralizers reveals multiple sites of vulnerability within HCMV Trimer and PentamerIn: Immunity Vol. 56 (2023) Nr. 11, pp. 2602 - 2620.e10Online Full Text: dx.doi.org/
-
Metabolic requirements of NK cells during the acute response against retroviral infectionIn: Nature Communications Vol. 12 (2021) Nr. 1, 5376Online Full Text: dx.doi.org/ Online Full Text (Open Access)
-
Neurological Manifestations of COVID-19 Feature T Cell Exhaustion and Dedifferentiated Monocytes in Cerebrospinal FluidIn: Immunity Vol. 54 (2021) Nr. 1, pp. 164Online Full Text: dx.doi.org/ Online Full Text (Open Access)
-
SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19In: Nature Communications Vol. 12 (2021) Nr. 1, pp. 1813Online Full Text: dx.doi.org/ (Open Access)
-
Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients With Chronic HBV Infection Naïve to Nucleos(t)ide TherapyIn: Gastroenterology Vol. 158 (2020) Nr. 8, pp. 2180 - 2194Online Full Text: dx.doi.org/ (Open Access)
-
Final results of a multicenter, open-label phase 2 clinical trial (MYR203) to assess safety and efficacy of myrcludex B in cwith PEG-interferon Alpha 2a in patients with chronic HBV/HDV co-infectionIn: Journal of Hepatology Vol. 70 (2019) Nr. 1 Suppl., pp. e81Online Full Text: dx.doi.org/
-
MMP2/MMP9-mediated CD100 shedding is crucial for inducing intrahepatic anti-HBV CD8 T cell responses and HBV clearanceIn: Journal of Hepatology Vol. 71 (2019) Nr. 4, pp. 685 - 698Online Full Text: dx.doi.org/
-
CEACAM1 promotes CD8⁺ T cell responses and improves control of a chronic viral infectionIn: Nature Communications Vol. 9 (2018) 2561Online Full Text: dx.doi.org/ (Open Access)
-
Combined toll-like receptor 3/7/9 deficiency on host cells results in T-cell-dependent control of tumour growthIn: Nature Communications Vol. 8 (2017) pp. 14600Online Full Text: dx.doi.org/ (Open Access)
-
Circulating HIV-Specific Interleukin-21In: Immunity Vol. 44 (2016) Nr. 1, pp. 167 - 178Online Full Text: dx.doi.org/ (Open Access)
-
BLT-humanized C57BL/6 Rag2⁻/⁻γc⁻/⁻CD47⁻/⁻ mice are resistant to GVHD and develop B- and T-cell immunity to HIV infectionIn: Blood Vol. 122 (2013) Nr. 25, pp. 4013 - 4020Online Full Text: dx.doi.org/ Online Full Text (Open Access)
-
Friend retrovirus infection of myeloid dendritic cells impairs maturation, prolongs contact to naïve T cells, and favors expansion of regulatory T cellsIn: Blood Vol. 110 (2007) Nr. 12, pp. 3949 - 3958Online Full Text: dx.doi.org/ (Open Access)